Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals…

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, May 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

So far, Altmetric has seen 1 news story.

Introduction Rituximab (Rituxan; Genentech) is a chimeric anti-CD20 monoclonal antibody widely used in non-Hodgkin lymphoma (NHL…